Author Affiliations: Stanford University School of Medicine, Stanford, California (Mr Yokell) (myokell@Stanford.edu); and Warren Alpert Medical School of Brown University, Providence, Rhode Island (Drs Green and Rich).
To the Editor: The Commentary by Drs Gugelmann and Perrone1 highlights the important role of prescription monitoring programs in the struggle against opioid misuse in the United States. Although the authors emphasized the uncertain efficacy of these programs in reducing opioid-related morbidity and mortality, we believe there are additional applications for these programs and alternate ways to assess their overall effect.
Yokell MA, Green TC, Rich JD. Prescription Drug Monitoring Programs. JAMA. 2012;307(9):912–913. doi:10.1001/jama.307.9.912-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: